- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
Patent holdings for IPC class A61K 31/4355
Total number of patents in this class: 712
10-year publication summary
|
50
|
55
|
46
|
55
|
40
|
43
|
50
|
42
|
43
|
23
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2700 |
25 |
| Boehringer Ingelheim International GmbH | 4732 |
14 |
| Bristol-myers Squibb Company | 4848 |
13 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2822 |
13 |
| Royalty Security, LLC | 24 |
13 |
| Genentech, Inc. | 3898 |
12 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 680 |
11 |
| Enanta Pharmaceuticals, Inc. | 431 |
11 |
| Merck Sharp & Dohme Corp. | 2202 |
10 |
| Merck Patent GmbH | 5825 |
10 |
| Novartis AG | 11042 |
9 |
| Merck Sharp & Dohme LLC | 3724 |
9 |
| Pfizer Inc. | 3331 |
8 |
| Amgen Inc. | 3985 |
7 |
| Board of Regents, The University of Texas System | 5689 |
7 |
| Abbvie Inc. | 1783 |
7 |
| Astellas Pharma Inc. | 1081 |
7 |
| eFFECTOR Therapeutics, Inc. | 68 |
7 |
| Vifor (International) AG | 141 |
7 |
| Incyte Corporation | 1000 |
6 |
| Other owners | 506 |